Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)

NCT ID: NCT05134974

Last Updated: 2023-08-29

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 368 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-11-18
• Study Completion Date: 2022-03-29

Brief Summary

The objectives of this study are:

• To evaluate the efficacy of Nyxol to expedite the reversal of pharmacologically-induced mydriasis across multiple mydriatic agents with an emphasis on phenylephrine
• To evaluate the efficacy of Nyxol to return subjects to baseline accommodation after worsening (with cycloplegic agents tropicamide and Paremyd)
• To evaluate the safety of Nyxol
• To evaluate any additional benefits of the reversal of pharmacologically-induced mydriasis
• To evaluate the systemic exposure of Nyxol on pharmacokinetic (PK) sampling

Detailed Description

A randomized, parallel arm, double-masked, placebo-controlled Phase 3 study in at least 330 randomized subjects, evaluating the safety and efficacy of Nyxol in subjects with pharmacologically-induced mydriasis.

Following the successful completion of screening, each subject will be stratified by eye color and then simultaneously be randomized to mydriatic agent (unmasked) and treatment (masked). Treatment randomization will be 2:1, Nyxol or placebo (vehicle). Stratification by iris color will be 1:1, light or dark rides. The mydriatic agent randomization will be 3:1:1 (2.5% phenylephrine, 1% tropicamide, and Paremyd).

At the treatment visit, subjects who have been randomized and stratified by iris color (1:1 [light/dark]) will receive one of three approved mydriatic agents approximately 1 hour prior to receiving study treatment. Measurements will be measured before (-1 hour /baseline) and 60 minutes after (maximum/0 minutes) the mydriatic agent instillation in each eye (i.e. right before the study treatment is administered), and at 30 minutes, 60 minutes, 90 minutes, 2 hours, 3 hours, 4 hours, and 6 hours after treatment dosing. Measurements will include pupil diameter (PD), distance and near visual acuity (VA), accommodation, and redness in each eye.

Blood sampling for Nyxol PK measurements will be conducted in a subset of approximately 30 adult subjects at approximately two select study sites.

At the Follow-Up Visit, which is 1 day after Visit 1, measurements will again be recorded 24 hours after treatment dosing.

Conditions

Mydriasis; Dilation

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Phentolamine Ophthalmic Solution 0.75%

2 drops in study eye and 1 drop in non-study eye, 1 hour post pharmacologically-induced mydriasis

Group Type: ACTIVE_COMPARATOR

Phentolamine Ophthalmic Solution 0.75%

Intervention Type: DRUG

0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist

Phentolamine Ophthalmic Solution Vehicle

2 drops in study eye and 1 drop in non-study eye, 1 hour post pharmacologically-induced mydriasis

Group Type: PLACEBO_COMPARATOR

Phentolamine Ophthalmic Solution Vehicle

Intervention Type: DRUG

Phentolamine Ophthalmic Solution Vehicle

Interventions

Phentolamine Ophthalmic Solution 0.75%

0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist

Intervention Type: DRUG

Phentolamine Ophthalmic Solution Vehicle

Phentolamine Ophthalmic Solution Vehicle

Intervention Type: DRUG

Other Intervention Names

Nyxol®; Nyxol

Eligibility Criteria

Inclusion Criteria

1. Males or females ≥ 12 years of age

2. Ability to comply with all protocol-mandated procedures independently and to attend all scheduled office visits

Exclusion Criteria

1. Clinically significant ocular disease as deemed by the Investigator (eg, glaucoma, corneal edema, uveitis, severe keratoconjunctivitis sicca) that might interfere with the study

2. Unwilling or unable to discontinue use of contact lenses at screening until study completion

3. Unwilling or unable to suspend use of topical medication at screening until study completion

4. Ocular trauma, ocular surgery, or non-refractive laser treatment within the 6 months prior to screening

5. Use of any topical prescription or over-the-counter (OTC) ophthalmic medications of any kind within 7 days of screening, with the exception of lid scrubs with OTC products (eg, OCuSOFT® lid scrub, SteriLid®, baby shampoo, etc.)

6. Recent or current evidence of ocular infection or inflammation in either eye (such as current evidence of clinically significant blepharitis, conjunctivitis, or keratitis). Subjects must be symptom-free for at least 7 days prior to screening

7. Closed or very narrow-angle that in the Investigator's opinion is potentially occludable if the subject's pupil is dilated

8. Prior participation in a study involving the use of Nyxol for the reversal of mydriasis

9. Known hypersensitivity or contraindication to α- and/or β-adrenoceptor antagonists

10. Clinically significant systemic disease (eg, uncontrolled diabetes, myasthenia gravis, cancer, hepatic, renal, endocrine, or cardiovascular disorders) that might interfere with the study

11. Participation in any investigational study within 30 days prior to screening

12. Resting heart rate (HR) outside the normal range (50-110 beats per minute) at the Screening Visit.

13. Hypertension with resting diastolic blood pressure (BP)>105 mmHg or systolic BP > 160 mmHg at the Screening Visit.

• Minimum Eligible Age: 12 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Ocuphire Pharma, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Clinical Site 10

Newport Beach, California, United States

Clinical Site 12

Westminster, California, United States

Clinical Site 9

Delray Beach, Florida, United States

Clinical Site 8

Longwood, Florida, United States

Clinical Site 6

Morrow, Georgia, United States

Clinical Site 1

Roswell, Georgia, United States

Clinical Site 13

Lake Villa, Illinois, United States

Clinical Site 5

Pittsburg, Kansas, United States

Clinical Site 2

Bloomington, Minnesota, United States

Clinical Site 15

Garner, North Carolina, United States

Clinical Site 4

Athens, Ohio, United States

Clinical Site 14

Shrewsbury, Pennsylvania, United States

Clinical Site 7

Warwick, Rhode Island, United States

Clinical Site 11

Sioux Falls, South Dakota, United States

Clinical Site 3

Memphis, Tennessee, United States

Countries

United States

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

OPI-NYXRM-302 (MIRA-3)

Identifier Type: -

Identifier Source: org_study_id